Biology Department (Physiology), McMaster University, Hamilton, ON, Canada.
Department of Health Sciences, Queen's University, Kingston, ON, Canada.
Int J Stroke. 2024 Mar;19(3):280-292. doi: 10.1177/17474930231206066. Epub 2023 Oct 27.
Telestroke systems operate through remote communication, providing distant stroke evaluation through expert healthcare providers. The aim of this study was to assess whether the implementation of a telestroke system influenced stroke treatment outcomes in acute ischemic stroke (AIS) patients compared with conventional in-person treatment.
The study group evaluated multiple studies from electronic databases, comparing telemedicine (TM) and non-telemedicine (NTM) AIS patients between 1999 and 2022. We aimed to evaluate baseline characteristics, critical treatment times, and clinical outcomes.
A total of 12,540 AIS patients were included in our study with 7936 (63.9%) thrombolyzed patients. Of the thrombolyzed patients, 4150 (51.7%) were treated with TM, while 3873 (48.3%) were not. The mean age of TM and NTM cohorts was 70.45 ± 4.68 and 70.42 ± 4.63, respectively (p > 0.05). Mean National Institute of Health Stroke Scale scores were comparable, with the TM group reporting a non-significantly higher mean (11.89 ± 3.29.6 vs. 11.13 ± 3.65, p > 0.05). No significant difference in outcomes was found for symptoms onset-to-intravenous tissue plasminogen activator (ivtPA) times (144.09 ± 18.87 vs. 147.18 ± 25.97, p = 0.632) and door-to-needle times (73.03 ± 20.04 vs. 65.91 ± 25.96, p = 0.321). Modified Rankin scale scores (0-2) were evaluated, and no significant difference was detected between cohorts (odds ratio (OR): 1.06, 95% confidence interval (CI): 0.89-1.29, p = 0.500). Outcomes did not indicate any significance between both cohorts for 90-day mortality (OR: 1.16, 95% CI: 0.94-1.43, p = 0.17) or symptomatic intracranial hemorrhage (OR: 0.99, 95% CI: 0.73-1.34, p = 0.93). Results between groups were also non-significant when analyzing the rate of thrombolysis with ivtPA (30.86%± 30.7 vs. 20.5%± 18.6, p = 0.372) and endovascular mechanical thrombectomy (11.8%± 11.7 vs. 18.7%± 18.9, p = 0.508).
The use of telestroke in the treatment of AIS patients is safe with minimal non-significant differences in long-term outcomes and rates of thrombolysis compared with face-to-face treatment. Further studies comparing the different methods of TM are needed to assess the efficacy of TM in stroke treatment.
远程卒中系统通过远程通信运行,通过专业医疗保健提供者对远程卒中进行评估。本研究的目的是评估与传统面对面治疗相比,远程卒中系统的实施是否会影响急性缺血性卒中(AIS)患者的治疗结果。
研究组评估了 1999 年至 2022 年期间来自电子数据库的多项研究,比较了远程医疗(TM)和非远程医疗(NTM)AIS 患者。我们旨在评估基线特征、关键治疗时间和临床结果。
我们的研究共纳入了 12540 名 AIS 患者,其中 7936 名(63.9%)接受了溶栓治疗。在溶栓治疗的患者中,4150 名(51.7%)接受了 TM 治疗,3873 名(48.3%)未接受 TM 治疗。TM 和 NTM 队列的平均年龄分别为 70.45±4.68 和 70.42±4.63(p>0.05)。国家卫生研究院卒中量表评分的平均值相当,TM 组报告的平均评分(11.89±3.29)略高,但无统计学意义,而 NTM 组报告的平均评分(11.13±3.65)略低(p>0.05)。症状发作至静脉内组织纤溶酶原激活物(ivtPA)时间(144.09±18.87 与 147.18±25.97,p=0.632)和门到针时间(73.03±20.04 与 65.91±25.96,p=0.321)无显著差异。评估了改良 Rankin 量表评分(0-2),两个队列之间未检测到显著差异(比值比(OR):1.06,95%置信区间(CI):0.89-1.29,p=0.500)。90 天死亡率(OR:1.16,95%CI:0.94-1.43,p=0.17)和症状性颅内出血(OR:0.99,95%CI:0.73-1.34,p=0.93)在两个队列之间也没有显著差异。当分析 ivtPA 溶栓率(30.86%±30.7 与 20.5%±18.6,p=0.372)和血管内机械血栓切除术(11.8%±11.7 与 18.7%±18.9,p=0.508)时,两组之间的结果也无统计学意义。
与面对面治疗相比,远程卒中系统用于治疗 AIS 患者是安全的,长期预后和溶栓率的差异极小且无统计学意义。需要进一步研究比较不同的 TM 方法,以评估 TM 在卒中治疗中的疗效。